HCV and HBV prevalence based on home blood self-sampling and screening history in the general population in 2016: contribution to the new French screening strategy

Brouard, Cécile; Saboni, Leïla; Gautier, Arnaud; Chevaliez, Stéphane; Rahib, Delphine; Richard, Jean-Baptiste; Barin, Francis; Larsen, Christine; Sommen, Cécile; Pillonel, Josiane; Delarocque-Astagneau, Elisabeth; Lydié, Nathalie; Lot, Florence

doi:10.1186/s12879-019-4493-2

Table 2 Risk exposure factors and prevention practices regarding HBV, HCV and HIV in BaroTest and 2016-Health Barometer samples, mainland France, 2016

From: HCV and HBV prevalence based on home blood self-sampling and screening history in the general population in 2016: contribution to the new French screening strategy

Characteristics		BaroTest (eligible, n = 17,781)				2016-HB (n = 20,032)
		Participants (n = 6,945)			Non participants (n = 10,836)
		wBT % ^a	wHB %^a		wHB %^a	wHB %^a
HCV endemicity in country of birth^b	Low	91.1	94.8	*******	91.4	92.4
HCV endemicity in country of birth^b	Intermediate or high	8.9	5.2		8.6	7.6
HBV endemicity in country of birth^c	Low	86.6	91.8	***	86.8	88.4
	Intermediate	10.2	6.2		9.7	8.4
	High	3.2	2.0		3.5	3.2
Healthcare or stays ≥3 months in Africa, Asia or Middle East	Yes	12.6	11.0	*	12.5	11.9
	No	87.4	89.0		87.5	88.1
Blood transfusion before 1992	Yes	6.3	6.8		6.2	6.0
	No	92.7	92.4		92.7	93.0
	Not specified	1.0	0.8		1.1	1.0
Drug use during lifetime	Yes, intravenous use with or without nasal use	0.6	0.5		0.4	0.4
	Yes, nasal use only	5.9	5.2		4.7	4.8
	No	93.5	94.3		94.9	94.8
Lived with or had sexual intercourse with an HBV-infected person	Yes	4.3	3.9		3.4	3.6
	No	95.3	95.8		96.2	96.0
	Not specified	0.4	0.3		0.4	0.4
Sex with other men during lifetime^d	Yes	3.8	3.7		3.9	3.7
	No	96.1	96.2		95.7	96.0
	Not specified	0.1	0.1		0.4	0.3
Sexually transmitted infection(s) in the previous 12 months^e	Yes	1.3	1.1		1.0	1.1
	No	98.7	98.9		99.0	98.9
Tattooing or piercing without single-use materials	Yes	2.1	2.0		2.1	2.0
Tattooing or piercing without single-use materials	No	97.9	98.0		97.9	98.0
HCV screening during lifetime	Yes	19.9	19.2		19.8	19.2
	No	76.2	77.0		76.4	76.9
	Not specified	3.9	3.8		3.8	3.9
HBV screening during lifetime	Yes	37.4	37.1	*	36.5	35.6
	No	59.2	59.5		60.9	61.4
	Not specified	3.4	3.4		2.6	3.0
HIV screening during lifetime	Yes	60.3	60.0	*******	56.7	57.8
	No	39.4	39.7		43.0	41.9
	Not specified	0.3	0.3		0.3	0.3
HBV vaccination	Yes	47.8	47.0	*******	44.7	46.1
	No	45.9	47.3		48.0	46.6
	Not specified	6.3	5.7		7.3	7.3

* P-value < 0.05, ** P value < 0.01, *** P value < 0.001 between BaroTest participants and non-participants wHB distributions using Chi-2 test
^awHB %: Health Barometer weighted percentage; wBT %: BaroTest weighted percentage
^bCountries with a low level of HCV endemicity: Europe, America, Caribbean; countries with an intermediate or high level of endemicity: Africa, Middle-East, Indian subcontinent, Asia, Pacific Islands
^cCountries with a low level of HBV endemicity: Northern and Western Europe, North America, Pacific Islands; countries with an intermediate level of endemicity: French Overseasadministrative areas, Eastern and Southern Europe, North Africa, Middle-East, Indian subcontinent, South America; countries with a high level of endemicity: Sub-Saharan Africa, Asia
^dAmong men who reported having had sexual relations in their lifetime (with men or women)
^eAmong individuals who reported having already had sexual relations in their lifetime. Mycosis are excluded
The distributions are significantly different for numbers in bold

Back to article page

ISSN: 1471-2334

Contact us

Submission enquiries: bmcinfectiousdiseases@biomedcentral.com
General enquiries: ORSupport@springernature.com

BMC Infectious Diseases

Contact us